936350-00-4

Basic information

• Product Name: GSK2190915
• Synonyms: GSK2190915;GSK2190915 (AM803);fiboflapon;AM 803;3-[(1,1-Dimethylethyl)thio]-1-[[4-(6-ethoxy-3-pyridinyl)phenyl]methyl]-alpha,alpha-dimethyl-5-[(5-methyl-2-pyridinyl)methoxy]-1H-indole-2-propanoic acid
• CAS NO: 936350-00-4
• Molecular Formula: C38H43N3O4S
• Molecular Weight: 637.83072
• Mol File: 936350-00-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 796.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• PKA: 4.70±0.10(Predicted)
• CAS DataBase Reference: GSK2190915(CAS DataBase Reference)
• NIST Chemistry Reference: GSK2190915(936350-00-4)
• EPA Substance Registry System: GSK2190915(936350-00-4)

Safety Data

• Hazardous Substances Data: 936350-00-4(Hazardous Substances Data)

Usage

General Description

GSK2190915 is a compound that has been studied for its potential therapeutic effects in the treatment of various diseases, including cancer and metabolic disorders. It is a selective and potent inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that plays a key role in regulating fatty acid biosynthesis and oxidation. By targeting and inhibiting ACC, GSK2190915 has the potential to reduce lipid accumulation and promote lipid oxidation, which could be beneficial in the treatment of diseases such as non-alcoholic fatty liver disease, obesity, and certain types of cancer that are dependent on lipid metabolism for their growth and survival. GSK2190915 has shown promising results in preclinical studies, and further research is ongoing to evaluate its safety and efficacy for various therapeutic indications.

Upstream product

• 1196965-16-8 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid ethyl ester 
• 4986-05-4 2,5-dimethylpyridine N-oxide 
• 936351-54-1 3-[1-(4-bromo-benzyl)-3-tert-butylsulfanyl-5-hydroxy-1H-indol-2-yl]-2,2-dimethyl-propionic acid ethyl ester 
• 772-71-4 2-acetoxymethyl-5-methyl pyridine 
• 1196965-14-6 3-{3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-hydroxy-1H-indol-2-yl}-2,2-dimethyl-propionic acid ethyl ester 
• 1346434-77-2 (5-methylpyridin-2-yl)methanol hydrochloride 
• 589-93-5 2,5-dimethylpyridine 
• 71670-70-7 2-(chloromethyl)-5-methyl-pyridine monohydrochloride 
• 1300640-30-5 2-(ethyloxy)-5-(4-{[1-(4-{[(5-methylpyridin-2-yl)methyl]oxy}phenyl)hydrazino]methyl}phenyl)pyridine 
• 136558-13-9 ethyl 5-t-butylthio-2,2-dimethyl-4-oxo-pentanoate 
• 59016-93-2 p-hydroxymethylphenylboronic acid 
• 55849-30-4 5-bromo-2-ethoxypyridine 
• 1300640-22-5 5-[4-(hydroxymethyl)phenyl]-2-(ethyloxy)pyridine 
• 1300640-23-6 5-[4-(bromomethyl)phenyl]-2-(ethyloxy)pyridine 

Relevant articles and documents

Novel Processes

The present invention provides processes useful for preparing 5-lipoxygenase activating protein (FLAP) inhibitors and their intermediates. In particular, processes for preparing 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, the anhydrous Form C polymorph of sodium 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate, and intermediates useful in said processes are provided.

5-Lipoxygenase-Activating Protein Inhibitor

Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of p